1201657-09-1

Basic information

• Product Name: 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole
• Synonyms: 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole;EOS-61651;trimethyl-[2-(1-methylpyrazol-4-yl)ethynyl]silane
• CAS NO: 1201657-09-1
• Molecular Formula: C₉H₁₄N₂Si
• Molecular Weight: 178.30636
• Mol File: 1201657-09-1.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole(1201657-09-1)
• EPA Substance Registry System: 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole(1201657-09-1)

Safety Data

• Hazardous Substances Data: 1201657-09-1(Hazardous Substances Data)

Usage

General Description

1-Methyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole is a chemical compound with the molecular formula C9H14N2Si. It is a pyrazole derivative containing a trimethylsilyl group and an ethynyl group. 1-Methyl-4-((triMethylsilyl)ethynyl)-1H-pyrazole is often used as a building block in organic synthesis and as a reagent in chemical reactions. It is a colorless liquid with a molecular weight of 174.30 g/mol. Its precise applications and properties can vary widely depending on the specific context and intended use in a chemical reaction or process.

Upstream product

• 39806-90-1 4-iodo-1-methyl-1H-pyrazole 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 39806-89-8 4-ethynyl-1-methyl-1-H-pyrazole 
• 1400285-26-8 tert-butyl 3-chloro-6-(2-chloro-4-(dimethylcarbamoyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1693758-51-8 (S)-2-amino-N-(1-(8-((1-methyl-1H-pyrazol-4-yl)ethynyl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1400286-33-0 N-(2-methoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine 
• 1400285-15-5 tert-butyl 6-((2-chloro-4-(pyrimidin-5-yl)phenyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-14-4 tert-butyl 6-((2-chloro-4-(pyrazin-2-yl)phenyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400284-82-3 tert-butyl 6-(2-chloro-4-(pyridin-3-yl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400284-80-1 tert-butyl 6-(2-chloro-4-(1-methyl-1H-imidazol-5-yl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400284-88-9 tert-butyl 6-(2-chloro-4-(oxazol-5-yl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400284-79-8 tert-butyl 6-(2-chloro-4-(1-methyl-1H-pyrazol-3-yl) phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400284-78-7 tert-butyl 6-(2-chloro-4-(1-methyl-1H-pyrazol-4-yl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-01-9 tert-butyl-6-(2-chloro-4-(S,S-dioxo-thiomorpholine-4-carbonyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-06-4 tert-butyl 6-(2-chloro-4-(4-(dimethylamino)piperidine-1-carbonyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-05-3 tert-butyl 6-(2-chloro-4-(4-methoxypiperidine-1-carbonyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors

The transforming growth factor type β receptor I (TGF-β R1, also known as activin-like kinase 5 or ALK5) plays a significant role in the pathogenesis of multiple diseases such as malignant tumors and tissue fibrosis. Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. Herein, a novel series of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives was synthesized and identified as ALK5 inhibitors. Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. Compound 8h also showed favorable pharmacokinetic profile and ameliorated hERG inhibition. More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity.

PI3 KINASE INHIBITORS AND USES THEREOF

Described herein are PI3 Kinase inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, cardiovascular diseases, and inflammatory diseases.

SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.